Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bcann is a specialized line of terpene-enriched medical cannabis products developed by Bazelet-Tech, designed to optimize therapeutic outcomes for complex neurological conditions such as Epilepsy and Autism Spectrum Disorder (ASD). The core technology involves the precise enrichment of standardized cannabis extracts with specific terpene profiles to leverage the "entourage effect," which suggests that cannabinoids and terpenes work synergistically to enhance efficacy and improve the safety profile. For Epilepsy, the formulation is tailored to modulate neuronal excitability and reduce seizure frequency. In the context of Autism Spectrum Disorder, the product aims to alleviate core symptoms including behavioral outbursts, anxiety, and communication challenges. These formulations are typically delivered as sublingual oils to ensure consistent dosing and reliable bioavailability, addressing the variability often associated with traditional medical cannabis use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bcann.